Eton Pharmaceutical Stock Discussion

$Eton Pharmaceutical (ETON.US)$
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
Eton Pharmaceuticals has acquired U.S. rights to Amglidia (glyburide oral suspension) from AMMTeK for treating neonatal diabetes mellitus.
The product, already approved by the European Medicines Agency since 2018, has received Orphan Drug Designation from the FDA. Amglidia is a patented liquid formulation targeting approximately 300 U.S. patients with neonatal dia...

$Eton Pharmaceutical (ETON.US)$ Reuters· 2 mins ago
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)

$Eton Pharmaceutical (ETON.US)$ Makin that new 52wk high🤫🥂

$Eton Pharmaceutical (ETON.US)$ Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen
1 MINUTE AGO, 6:30 AM EDT
VIA GLOBENEWSWIRE
Aligns with Eton's Mission to Develop and Distribute Medicines that Have a Life Changing Impact for Patients with Ultra-rare Conditions
Acquisition to Bolster Eton's Commercial Pediatric Endocrinology Portfolio! Transaction Financed by Eton's Cash and Expanded Credit Facility

$Eton Pharmaceutical (ETON.US)$ like to see some accumulation at this level

$Eton Pharmaceutical (ETON.US)$ Eton Pharmaceuticals Inc: Prescription Drug User Fee Act (Pdufa) Target Action Date Is February 28, 2025

$Eton Pharmaceutical (ETON.US)$ ETON PHARMACEUTICALS INC - ET-400 PATENT PROTECTION THROUGH 2043

$Eton Pharmaceutical (ETON.US)$ Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for Et-400 (Hydrocortisone Oral Solution)

$Eton Pharmaceutical (ETON.US)$ Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
-- Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13(th) straight quarter of sequential product sales growth
-- Acquired PKU GOLIKE(R), launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400